Literature DB >> 22447299

Spinal mechanism underlying the antiallodynic effect of gabapentin studied in the mouse spinal nerve ligation model.

Shin-ichi Morimoto1, Masanori Ito, Satoko Oda, Atsushi Sugiyama, Masaru Kuroda, Satomi Adachi-Akahane.   

Abstract

We studied the antiallodynic effect of gabapentin (GBP) in the mouse model of neuropathic pain, aiming at clarifying the underlying mechanism. The L5 spinal nerve ligation induced tactile allodynia, an increase of CD11b expression, and an increase in the protein expression level of the voltage-dependent Ca(2+) channel α(2)/δ-1 subunit in the spinal dorsal horn on the injured side. The chronic intrathecal administration of GBP (100 µg/body per day) as well as ω-conotoxin MVIIA, an N-type Ca(2+)-channel blocker, completely suppressed allodynia, but did not attenuate the CD11b expression. The antiallodynic effect of GBP lasted for several days after the termination of the drug, while that of ω-conotoxin MVIIA disappeared immediately after the termination. GBP suppressed the elevation of the protein level of the α(2)/δ-1 subunit in the spinal dorsal horn, although it did not affect its mRNA level in the L5 DRG. These results suggest that GBP inhibits the development of allodynia by suppressing the up-regulation of N-type Ca(2+) channels, through normalization of the protein level of the α(2)/δ-1 subunit at the primary afferent nerve terminal via the inhibition of its anterograde transport. In addition, we propose that the nerve injury enhances the expression level of α(2)/δ-1 in the downstream of the activation of microglia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22447299     DOI: 10.1254/jphs.11102fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  6 in total

1.  Spinal actions of ω-conotoxins, CVID, MVIIA and related peptides in a rat neuropathic pain model.

Authors:  A Jayamanne; H J Jeong; C I Schroeder; R J Lewis; M J Christie; C W Vaughan
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

Review 2.  Neuropathic Pain and Spinal Cord Injury: Phenotypes and Pharmacological Management.

Authors:  Eva Widerström-Noga
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

Review 3.  Pregabalin for chemotherapy-induced neuropathy: background and rationale for further study.

Authors:  Mellar Davis; Charles Loprinzi
Journal:  Support Care Cancer       Date:  2022-08-11       Impact factor: 3.359

Review 4.  Improving the translation of analgesic drugs to the clinic: animal models of neuropathic pain.

Authors:  N Percie du Sert; A S C Rice
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

5.  Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept.

Authors:  Hue Jung Park; Jennifer A Stokes; Elaine Pirie; James Skahen; Yuri Shtaerman; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-12-07       Impact factor: 5.108

6.  Pathogenic Mechanism of Dry Eye-Induced Chronic Ocular Pain and a Mechanism-Based Therapeutic Approach.

Authors:  Yuto Tei; Yoshinori Mikami; Masanori Ito; Taichiro Tomida; Daisuke Ohshima; Yuichi Hori; Satomi Adachi-Akahane
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-01-03       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.